Victoza (Liraglutide) Dosing and Administration
Standard Dosing Protocol
Victoza should be initiated at 0.6 mg subcutaneously once daily for one week, then increased to 1.2 mg once daily, with optional escalation to the maximum dose of 1.8 mg once daily if additional glycemic control is needed after at least one week at 1.2 mg. 1 The initial 0.6 mg dose is specifically designed to reduce gastrointestinal symptoms during titration and is not effective for glycemic control—it serves solely as a tolerability step. 1
Dosing Schedule
- Week 1: 0.6 mg once daily (tolerability dose only)
- Week 2 onward: 1.2 mg once daily (standard maintenance dose)
- Optional escalation: 1.8 mg once daily after ≥1 week at 1.2 mg if HbA1c targets are not met 1
Pediatric Dosing (Age 10 Years and Older)
Start at 0.6 mg once daily, then increase in 0.6 mg increments after at least one week on each dose, up to a maximum of 1.8 mg once daily. 1
Administration Details
Inject Victoza subcutaneously once daily at any time of day, independently of meals, in the abdomen, thigh, or upper arm. 1 Rotate injection sites within the same region to reduce the risk of cutaneous amyloidosis. 1 When using Victoza with insulin, administer as separate injections—never mix—though injections may be given in the same body region if not adjacent to each other. 1
Missed Dose Management
If a dose is missed, resume the regular once-daily schedule with the next scheduled dose—do not administer an extra dose or increase the dose to compensate. 1 If more than 3 days have elapsed since the last dose, reinitiate Victoza at 0.6 mg once daily to mitigate gastrointestinal symptoms, then retitrate at the healthcare provider's discretion. 1
Absolute Contraindications
Victoza is contraindicated in patients with:
- Personal or family history of medullary thyroid carcinoma (MTC) 1
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 1
- Serious hypersensitivity reaction to liraglutide or any excipient 1
Concomitant Medication Adjustments
When initiating Victoza in patients on sulfonylureas, reduce the sulfonylurea dose to lower hypoglycemia risk, as the glucose-dependent insulin secretion from Victoza adds to the sulfonylurea's effect. 2, 3 Daily blood glucose monitoring is not routinely required with Victoza monotherapy but may be necessary when combined with a sulfonylurea. 2
Renal and Hepatic Considerations
No dose adjustment is required for renal or hepatic impairment, though therapeutic experience in patients over 75 years of age is limited. 2, 3
Expected Efficacy and Safety Profile
Victoza typically reduces HbA1c by at least 1% and induces moderate weight loss without causing hypoglycemia when used as monotherapy or with metformin. 3, 4 The most common adverse events are gastrointestinal (nausea, vomiting, diarrhea), which are usually mild to moderate, occur during the initial treatment phase, and diminish over time. 3, 4 The low risk of hypoglycemia is due to Victoza's glucose-dependent mechanism of insulin stimulation. 2, 3
Cardiovascular Indication
Victoza is indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease. 1
If Glycemic Control Is Insufficient at Maximum Dose
If HbA1c targets are not achieved after at least one week at the maximum 1.8 mg daily dose, consider adding or intensifying other glucose-lowering medications rather than exceeding the approved maximum dose. 1 The 1.8 mg dose represents the ceiling for Victoza efficacy—further dose escalation is not supported. 1